Development: Preclinical Model Based Drug Development

  • Aleš Prokop
  • Seth Michelson
Part of the SpringerBriefs in Pharmaceutical Science & Drug Development book series (BRIEFSPSDD, volume 2)


Large scale in silico clinical development will only become a reality after some effort is exerted; some partial solutions (SB and BI tools mentioned in previous chapters) already exist and first attempts have been made. We acknowledge here that we are NOT in square zero and that in silico technologies have been, and are already being, used in clinical trial design and execution, used in simulation studies for adaptive trials, and used to identify patient subpopulations and markers for enrichment strategies. This goal will require a concentrated effort by all players, with considerable investment from the pharma industry and governments.


Clinical Trial Design Learning Cycle Process Analytical Technology Enrichment Strategy Adaptive Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R (2007) Model-based drug development. Clin Pharmacol Ther 82(1):21–32PubMedCrossRefGoogle Scholar
  2. 2.
    Powell JR, Gobburu JV (2007) Pharmacometrics at FDA: evolution and impact on decisions. Clin Pharmacol Ther 82(1):97–102PubMedCrossRefGoogle Scholar
  3. 3.
    Gobburu JV, Lesko LJ (2009) Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol 49:291–301PubMedCrossRefGoogle Scholar
  4. 4.
    Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61:275–291PubMedCrossRefGoogle Scholar
  5. 5.
    Allerheiligen SR (2010) Next-generation model-based drug discovery and development: quantitative and systems pharmacology. Clin Pharmacol Ther 88(1):135–137PubMedCrossRefGoogle Scholar
  6. 6.
    Wetherington JD, Pfister M, Banfield C, Stone JA, Krishna R, Allerheiligen S, Grasela DM (2010) Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development. J Clin Pharmacol 50(9 Suppl):31S–46SPubMedCrossRefGoogle Scholar
  7. 7.
    Suryawanshi S, Zhang L, Pfister M, Meibohm B (2010) The current role of model-based drug development. Expert Opin Drug Discov 5(4):311–321CrossRefGoogle Scholar
  8. 8.
    Keizer RJ, Schellens JH, Beijnen JH, Huitema AD (2011) Pharmacodynamic biomarkers in model-based drug development in oncology. Curr Clin Pharmacol 6(1):30–40PubMedCrossRefGoogle Scholar
  9. 9.
    Nasr MM (2006) FDA, DIA meeting Philadelphia, PA, USAGoogle Scholar
  10. 10.
    Lutze P, Román-Martinez A, Woodley JM, Gani R (2010) A systematic synthesis and design methodology to achieve process intensification in (bio) chemical processes. In: Pierucci S, Buzzi Ferraris G (eds) 20th European symposium on computer aided process engineering—ESCAPE20, ElsevierGoogle Scholar

Copyright information

© The Author(s) 2012

Authors and Affiliations

  1. 1.Chemical and Biomolecular EngineeringVanderbilt UniversityNashvilleUSA
  2. 2.NanoDelivery International, s.r.o.Břeclav-PoštornáCzech Republic
  3. 3.Genomic Health IncRedwood CityUSA

Personalised recommendations